98%
921
2 minutes
20
Objectives: The association between specific types of malignancies and the subsequent risk of dementia remains unknown.
Design: A retrospective population-based cohort study based on data from Taiwan National Health Insurance Research Database.
Setting And Participants: We recruited 32,250 patients who survived malignancies and 322,500 controls between 1998 and 2011 and followed them up until the end of 2013.
Measurements: Diagnoses of dementia (including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia) was made during the follow-up period. Cox regression analyses were performed after adjusting for potential confounders. A sensitivity analysis was conducted to exclude patients with prodromal dementia.
Results: Cancer survivors were more likely to develop AD (hazard ratio [HR]: 1.68, 95% confidence interval [CI]: 1.38-2.06), unspecified dementia (HR: 1.19, 95% CI: 1.07-1.32), and any dementia (HR: 1.26, 95% CI: 1.16-1.37) compared with controls after adjusting for potential confounders. Importantly, cancers of the digestive and genitourinary organs seem to be associated with AD, unspecified dementia, and any dementia, whereas only malignant neoplasms of the brain are more likely to develop into VaD. Sensitivity analyses after exclusion of the first three or five years of observation and after exclusion of case enrollment before 2009 or 2007 showed consistent findings.
Conclusion: Cancer survivors are at higher risk of subsequent dementia. Different types of cancer survivors may contribute to variable risks of specific dementias. Further studies are necessary to investigate the underlying mechanisms in cancer survivors and patients with dementia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jagp.2024.07.013 | DOI Listing |
EClinicalMedicine
October 2025
Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, 686 Bay St., Toronto, Ontario, Canada.
Background: While testicular germ cell tumors (TGCT) survival exceeds 90%, many survivors of adult TGCT are at risk for treatment toxicities. Less is known about physical morbidities in children, adolescents, and young adults (CAYA) with TGCT.
Methods: We used the Pediatric Oncology Group of Ontario Networked Information System, the Initiative to Maximize Progress in Adolescent and Young Adult Cancer Therapy, and the Ontario Cancer Registry to identify all CAYA males diagnosed with TGCT from 1992 to 2021 at age 11-21 years in Ontario, Canada.
Radiat Res
September 2025
Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.
Contralateral breast (CB) cancer is the most common subsequent cancer among breast cancer survivors, and radiotherapy has been linked to CB cancer risk. The purpose of this work was to evaluate doses to subregions of the contralateral breast from historical breast cancer treatments carried out in the United States between 1990 and 2012. We extracted treatment data from radiation therapy summaries for 2,442 radiotherapy patients during that period.
View Article and Find Full Text PDFRev Recent Clin Trials
September 2025
Department of Radiation Oncology, University Hospital of Iraklion, 71110, Iraklion, Greece.
Introduction: Radiotherapy (RT) is an integral component of various multidisciplinary treatment approaches for pelvic malignancies, used both in the radical and adjuvant setting. Despite the improvement of radiotherapy modalities, pelvic radiotherapy often induces permanent erectile dysfunction (ED). However, post-treatment ED receives little medical attention, since patient follow-up focuses mainly on cancer recurrence surveillance.
View Article and Find Full Text PDFJ Natl Cancer Inst
September 2025
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States.
Background: Among childhood cancer survivors, germline rare variants in autosomal dominant cancer susceptibility genes (AD CSGs) could increase subsequent neoplasm (SNs) risks, but risks for rarer SNs and by age at onset are not well understood.
Methods: We pooled the Childhood Cancer Survivor Study and St Jude Lifetime Cohort (median follow-up = 29.7 years, range 7.
PLoS One
September 2025
Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Background: Current aftercare in breast cancer survivors aims to detect local recurrences or contralateral disease, while the detection of distant metastases has not been a central focus due to a lack of evidence supporting an effect on overall survival. However, the data underpinning these guidelines are mainly from trials of the 1980s/1990s and have not been updated to reflect the significant advancements in diagnostic and therapeutic options that have emerged over the past 40 years. In this trial, the aim is to test whether a liquid biopsy-based detection of (oligo-) metastatic disease at an early pre-symptomatic stage followed by timely treatment can impact overall survival compared to current standard aftercare.
View Article and Find Full Text PDF